NAT2 and prostate carcinoma: In our study, we found that the NAT2 slow acetylator phenotype was associated with an increased risk of prostate cancer (OR, 1.65; 95% CI, 1.04–2.61) (Table 4) and that the NAT2 slow acetylator phenotype (OR, 5.29; 95% CI, 2.37–11.80; P for interaction, 0.004) was higher than rapid or intermediate acetylator phenotypes (OR, 1.85; 95% CI, 1.34–2.56) among individuals with high HAA intake (Table 5).